SEC Imposes $30 Million Penalty on Zymergen Inc. for Misleading IPO Investors
The U.S. Securities and Exchange Commission (SEC) has charged Zymergen Inc., a bankrupt biotechnology company based in Emeryville, California, with misleading investors during its initial public offering (IPO) in April 2021. The SEC announced the settled charges on September 13, 2024, highlighting serious misrepresentations about the company's market potential, revenue prospects, and customer pipeline for its primary product, Hyaline.